These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33069923)

  • 1. Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice.
    Brent MB; Lodberg A; Bromer FD; van der Eerden BCJ; Eijken M; Brüel A; Thomsen JS
    Bone; 2021 Jan; 142():115692. PubMed ID: 33069923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTH (1-34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats.
    Brent MB; Brüel A; Thomsen JS
    Bone; 2018 May; 110():244-253. PubMed ID: 29475111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats.
    Brüel A; Vegger JB; Raffalt AC; Andersen JE; Thomsen JS
    Bone; 2013 Mar; 53(1):51-8. PubMed ID: 23246791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia.
    Lodberg A; Eijken M; van der Eerden BCJ; Okkels MW; Thomsen JS; Brüel A
    Bone; 2018 May; 110():326-334. PubMed ID: 29499419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.
    Vegger JB; Nielsen ES; Brüel A; Thomsen JS
    Bone; 2014 Sep; 66():287-95. PubMed ID: 24970039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar.
    Brent MB; Thomsen JS; Brüel A
    Front Endocrinol (Lausanne); 2020; 11():588773. PubMed ID: 33162940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats.
    Brent MB; Brüel A; Thomsen JS
    Bone; 2022 Jul; 160():116417. PubMed ID: 35398589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice.
    Sørensen TG; Brent MB; Thomsen JS; Brüel A
    Bone; 2020 Feb; 131():115183. PubMed ID: 31794846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rodent model of disuse-induced bone loss by hind limb injection with botulinum toxin A.
    Brent MB; Lodberg A; Thomsen JS; Brüel A
    MethodsX; 2020; 7():101079. PubMed ID: 33083241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone mitigates loss of periosteal bone formation and muscle mass in disuse osteopenic rats.
    Grubbe MC; Thomsen JS; Nyengaard JR; Duruox M; Brüel A
    J Musculoskelet Neuronal Interact; 2014 Dec; 14(4):473-83. PubMed ID: 25524973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone anabolic effects of separate and combined therapy with growth hormone and parathyroid hormone on femoral neck in aged ovariectomized osteopenic rats.
    Wang L; Orhii PB; Banu J; Kalu DN
    Mech Ageing Dev; 2001 Jan; 122(1):89-104. PubMed ID: 11163626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgens have antiresorptive effects on trabecular disuse osteopenia independent from muscle atrophy.
    Laurent MR; Jardí F; Dubois V; Schollaert D; Khalil R; Gielen E; Carmeliet G; Claessens F; Vanderschueren D
    Bone; 2016 Dec; 93():33-42. PubMed ID: 27622887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAGE supports parathyroid hormone-induced gains in femoral trabecular bone.
    Philip BK; Childress PJ; Robling AG; Heller A; Nawroth PP; Bierhaus A; Bidwell JP
    Am J Physiol Endocrinol Metab; 2010 Mar; 298(3):E714-25. PubMed ID: 20028966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice.
    Vegger JB; Brüel A; Thomsen JS
    J Musculoskelet Neuronal Interact; 2017 Sep; 17(3):162-175. PubMed ID: 28860418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Normobaric Intermittent Hypoxia Therapy on Bone in Normal and Disuse Osteopenic Mice.
    Bromer FD; Brent MB; Pedersen M; Thomsen JS; Brüel A; Foldager CB
    High Alt Med Biol; 2021 Jun; 22(2):225-234. PubMed ID: 33769867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
    Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
    Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activin receptor signaling: a potential therapeutic target for osteoporosis.
    Lotinun S; Pearsall RS; Horne WC; Baron R
    Curr Mol Pharmacol; 2012 Jun; 5(2):195-204. PubMed ID: 21787285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.
    Saidak Z; Le Henaff C; Azzi S; Marty C; Marie PJ
    J Endocrinol; 2014 Oct; 223(1):25-33. PubMed ID: 25056116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats.
    Lane NE; Thompson JM; Strewler GJ; Kinney JH
    J Bone Miner Res; 1995 Oct; 10(10):1470-7. PubMed ID: 8686502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.